Welcome to IH Saltz! The more I read about CCR5
Post# of 155583
(Total Views: 347)
Posted On: 04/16/2019 5:24:18 PM
Welcome to IH Saltz!
The more I read about CCR5's role in cancer / cancer metastasis, the more optimistic I become on leronlimab working and transforming deadly cancer as we currently know.
There are plenty of other articles noting the role of CCR5 in cancer, but here is one example of my optimism from Dr. Pestell's, Dr. Cristofanilli's and Dr. Jaio's CTC Patent:
www.freepatentsonline.com/y2018/0303830.html
If leronlimab works, I believe it will benefit a minimum of 30% of cancer patients. Based on the numbers below, 90% of 606,880 = 546,192 or just under 31% of the 1,762,450 estimated cancer diagnosis in the US in 2019. These numbers only reflect the most severe cancer diagnosis, which if leronlimab is proven to prevent metastasis, I would bet any cancer patient that expresses CCR5 and/or a certain level of CTCs will be put on leronlimab. I know this is combining 2 different stats that are somewhat independent in the estimated 2019 new cancer diagnosis and deaths (which a large portion is likely pre-2019 diagnosis).
"Metastasis is the general term used to describe the spread of cancer cells from the primary tumor to surrounding tissues and to distant organs and is the primary cause of cancer morbidity and mortality. It is estimated that metastasis is responsible for about 90% of cancer deaths."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597235/
"About 606,880 Americans are expected to die of cancer in 2019 (Table 1), which translates to about 1,660 deaths per day."
https://www.cancer.org/content/dam/cancer-org...s-2019.pdf
You may have other stats, but these are some I found recently and thought I would share. Positive cancer results will transform CYDY.....until then I'm patiently waiting.
The more I read about CCR5's role in cancer / cancer metastasis, the more optimistic I become on leronlimab working and transforming deadly cancer as we currently know.
There are plenty of other articles noting the role of CCR5 in cancer, but here is one example of my optimism from Dr. Pestell's, Dr. Cristofanilli's and Dr. Jaio's CTC Patent:
www.freepatentsonline.com/y2018/0303830.html
If leronlimab works, I believe it will benefit a minimum of 30% of cancer patients. Based on the numbers below, 90% of 606,880 = 546,192 or just under 31% of the 1,762,450 estimated cancer diagnosis in the US in 2019. These numbers only reflect the most severe cancer diagnosis, which if leronlimab is proven to prevent metastasis, I would bet any cancer patient that expresses CCR5 and/or a certain level of CTCs will be put on leronlimab. I know this is combining 2 different stats that are somewhat independent in the estimated 2019 new cancer diagnosis and deaths (which a large portion is likely pre-2019 diagnosis).
"Metastasis is the general term used to describe the spread of cancer cells from the primary tumor to surrounding tissues and to distant organs and is the primary cause of cancer morbidity and mortality. It is estimated that metastasis is responsible for about 90% of cancer deaths."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597235/
"About 606,880 Americans are expected to die of cancer in 2019 (Table 1), which translates to about 1,660 deaths per day."
https://www.cancer.org/content/dam/cancer-org...s-2019.pdf
You may have other stats, but these are some I found recently and thought I would share. Positive cancer results will transform CYDY.....until then I'm patiently waiting.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.